
Cupid Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
No
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Female condom sales projected robust at around INR 32 crores in FY '24 despite current challenges.
- Expect gradual growth in IVD (In Vitro Diagnostics) business, targeting INR 2 crores sales in FY '24, with potential rise to INR 50-100 crores in 2-3 years.
- International market expansion ongoing, with export reach now in 105 countries, including new additions in Europe and Africa.
- Anticipated resumption and growth in South African sales starting August 2023, with new tender expected from Brazil worth INR 25-30 crores.
- Order book currently at INR 104 crores with expectations of additional orders from Brazil, UNFPA, and South Africa.
- Capacity expansion potential, e.g., female condom capacity increase from 25 million to 52 million pieces if demand arises.
- Long-term focus on export markets where demand and margins are higher compared to domestic sales.
See what Cupid management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company is considering selling promoter stakes, primarily for personal reasons, with no fixed percentage or mode (IPO or preference shares) decided yet. They are open to offers including from DIIs and FIIs.
- There is no confirmed large capital expenditure except a potential INR12 crore land purchase next to the factory for future expansion.
- For the IVD business, capital requirements are estimated at INR3-4 crores before sales pick up and may increase to INR35-40 crores post-certifications in FY '25 and '26.
- There is no specific mention of new fundraising through debt.
- The company is reviewing all options including utilization of reserves, dividend payments, and business expansion investments.
See what Cupid management said on order book — free account, 30 seconds.
Capex plans
Yes- Cupid Limited plans a capital investment of about INR 12 crores to buy land adjacent to its current factory for future expansion.
- There is no major capex expected in the next 2-3 years apart from this land purchase.
- The company is also considering business expansion by increasing production capacity for both male and female condoms.
- For the IVD (In Vitro Diagnostics) business, the company expects higher working capital requirements around INR 30-40 crores as sales scale up post-certifications in FY 25 and 26.
- No finalized decisions on new corporate FD investments; current investments include bank FDs and mutual funds.
- Promoters are considering selling their stake mainly for personal reasons but remain open regarding the quantity and mode of sale.
Track Cupid — get its next earnings analysis in your feed
How does Cupid rank vs peers in Personal Products?
Pro featureHow does Cupid rank in Personal Products?
Compare Cupid against every Personal Products company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Cupid's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare (Q2 FY27)
Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare
- Gillette India (Q2 FY27)
Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear
- Honasa Consumer (Q2 FY27)
Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…
- Emami (Q2 FY27)
Volume growth for domestic business recorded 43% in Q2 and 26% on a like-to-like basis, indicating strong demand. Key concall takeaways from Emami Ltd's Q2…